Organization
Rochester, MN
28 abstracts
Abstract
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Johns Hopkins University, Baltimore, MD,
Abstract
Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Alliance Statistics and Data Management Center, Mayo Clinic Rochester,
Abstract
Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.Org: Mayo Clinic Department of Radiation Oncology, Rochester, MN, Mayo Clinic, Phoenix, AZ, Division of Hematology & Medical Oncology,
Abstract
Neuro-oncology anywhere: A decentralized approach to clinical trials in brain tumors and beyond.Org: Mayo Clinic, Rochester, MN,
Abstract
Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer.Org: University of Kansas Medical Center, Mayo Clinic, Mayo Clinic Cancer Center, Washington University in St. Louis, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute,
Abstract
Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC).Org: Mayo Clinic, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, University of Michigan, Duke University Medical Center/Duke Cancer Institute,
Abstract
Differences in physical and emotional distress amongst patients undergoing neoadjuvant chemotherapy versus surgery for advanced ovarian cancer: Patient-reported outcomes at diagnosis.Org: Mayo Clinic, Rochester, MN,
Abstract
Understanding fellow hematology curriculums: Characterizing perspectives and defining opportunities for improvement.Org: Mayo Clinic, Rochester, MN,
Abstract
Effect of AURKA targeting on nuclear PD-L1 and the efficacy of immune checkpoint inhibitors in triple-negative breast cancer.Org: Mayo Clinic, Rochester, MN,
Abstract
Class comparison of BCMA-directed therapies in relapsed multiple myeloma.Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic, Rochester, MN, Mayo Clinic Florida, Jacksonville, FL,
Abstract
Association of human interpretable features derived from pancreatic ductal adenocarcinoma pathology slides with disease-free survival.Org: Mayo Clinic, Rochester, MN,
Abstract
Symptom burden in adolescents and young adults with cancer: A subgroup analysis of the enhanced, EHR-facilitated cancer symptom control (E2C2) trial.Org: Mayo Clinic, Rochester, MN, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indianapolis, IN, Scottsdale, AZ,
Abstract
Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS).Org: Duke Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Durham, NC, Mayo Clinic, Rochester, MN,
Abstract
Strategies to increase accrual of underrepresented populations in Alliance NCTN trials.Org: The Ohio State University - James Cancer Hospital, Columbus, OH, Alliance NCTN Foundation, Chicago, IL, University of Colorado Denver Anschutz Medical Center,
Abstract
AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.Org: Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, University of Chicago, Chicago, IL,
Abstract
A first-in-human pharmacodynamic evaluation of dual polyamine depletion for patients with high-grade gliomas.Org: Mayo Clinic, Rochester, MN,
Abstract
A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE).Org: Mayo Clinic, Rochester, MN, Phoenix, AZ, Jacksonville, FL, Clear Lake Oncology,
Abstract
First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of WSD0922-Fu: Initial report from dose escalation cohort.Org: Mayo Clinic, Rochester, MN, Jacksonville, FL, Phoenix, AZ, Wayshine Biopharm,
Abstract
Trends in new and persistent opioid use in older adults with cancer.Org: Yale School of Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New Haven, CT, Cancer Outcomes, Public Policy and Effectiveness Research Center, Public Policy and Effectiveness Research (COPPER) Center,
Abstract
An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.Org: Mayo Clinic, Scottsdale, AZ, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Hospital, Baltimore, MD,
Abstract
Outcomes by time to adjuvant therapy in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.Org: Hillman Cancer Center, Pittsburgh, PA, Pittsburgh, PA, Dana Farber Cancer Institute – ECOG-ACRIN Biostatistics Center, Boston, MA, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Abstract
PolyPEPI1018 vaccine in combination with TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC): A phase Ib study to evaluate safety, tolerability, immunogenicity and efficacy (OBERTO-201).Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Mayo Clinic, Rochester, MN, Department of Laboratory Medicine and Pathology, University of Washington, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Baseline characteristics identifying patients (pts) with multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel; bb2121) who are at risk for severe/refractory inflammatory adverse events (iAEs).Org: Bristol Myers Squibb, Princeton Health, Lille University Hospital, Lille, France, Mayo Clinic,
Abstract
Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial.Org: Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, Fox Chase Cancer Center, Temple University Health System,
Abstract
A multi-component educational intervention for oncologists to improve tobacco cessation treatment among patients with cancer who smoke.Org: Mayo Clinic, Rochester, MN,
Abstract
Tolerability of lutetium-177–PSMA-617 in men with prostate cancer and baseline cytopenia.Org: Mayo Clinic, Rochester, MN, Mayo Clinic - Rochester, MN,
Abstract
Systematic review determining the characteristics of primary bone lymphoma.Org: University of Texas Health Science Center at San Antonio, San Antonio, TX, UT Health San Antonio, MD Anderson Cancer Center, Mayo Clinic, Rochester, MN,
Abstract
Risk and protective factors for dementia in cancer survivors vary by cancer type.Org: Mayo Clinic, Rochester, MN,